Profile of Injured Singers: Expectations and Insights

xlomafota13 shared this article with you from Inoreader Profile of Injured Singers: Expectations and Insights Via The Laryngoscope Objectives To discover patterns of phonotraumatic lesions in singers and investigate factors that differentiate those who underwent surgery from those who did not. We hypothesized that 1) lesion type distribution differs by age, sex, singer classification (professional/amateur), and history of formal voice training; 2) the likelihood of surgery is associated with singer classification and voice training. Study Design Retrospective. Methods Retrospective review of 438 singers with phonotraumatic lesions over a 9-year period. Lesion type distribution was analyzed with respect to sex, age, singer classification, and voice training. The association of eventual surgery with these factors was also analyzed. Results Nodules accounted for over half of the cohort (58%), followed by pseudocysts (20%), polyps (14%), and cysts (4%). Nearly two of every three injured female singers, but fewer than one out of every three injured male singers, had nodules. In contrast, over half of the injured males had polyps, whereas only 6% of injured females had polyps. In females, polyps occurred at a later age, and in males, nodules occurred at a younger age compared to other lesion types. Only 14% of the total cohort eventually underwent surgery. Professional singers without formal voice training were almost eight times more likely to have undergone surgery than amateur singers with voice training. Conclusions Professional singers were more likely to undergo surgery than amateurs, and formal voice training was associated with a lower likelihood of surgery. The observation that polyps tended to occur in older women may have implications for the pathogenesis of vocal fold polyps. Level of Evidence 4 Laryngoscope, 2022 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

FOCUS THEME ISSUE: CONCISE COMMUNICATION Dysbiosis of nail microbiome in patients with psoriasis

xlomafota13 shared this article with you from Inoreader FOCUS THEME ISSUE: CONCISE COMMUNICATION Dysbiosis of nail microbiome in patients with psoriasis Via Experimental Dermatology ABSTRACT Shifts in skin microbiome are considered to be involved in the pathogenesis of psoriasis. However, data on the microbial dysbiosis of nail psoriasis is scarce. In this study, we aim to investigate and characterize the nail bacterial and fungal microbiome in patients with psoriasis. Nail samples were collected prospectively from 36 subjects with nail psoriasis, 24 psoriatic subjects without nail involvement, and 32 healthy controls. Amplicon sequencing was performed to evaluate the bacterial and fungal community compositions. Significant alterations in the bacterial microbiome were found in the nail samples of psoriatic patients. The unaffected nails in psoriatic patients were associated with higher bacterial diversity, and a higher relative abundance of Enhydrobacter, whereas nail psoriasis was correlated with a decreased relative abundance of Anaerococcus. Shifts in fungal community composition was reflected by a higher proportion of Malassezia in the unaffec ted nails of psoriatic patients and an increased proportion of Candida in psoriatic nails. Shifts in the nail microbiome in psoriasis suggest a potential role of microbes in the development of nail psoriasis. Future researches focusing on these microorganisms may help to explain the pathogenesis of psoriasis. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Specificities of supportive care in geriatric oncology

xlomafota13 shared this article with you from Inoreader Specificities of supportive care in geriatric oncology Via Association française pour l'étude du cancer Bull Cancer. 2022 Jan 10:S0007-4551(21)00679-2. doi: 10.1016/j.bulcan.2021.12.004. Online ahead of print. ABSTRACT Supportive care in geriatric oncology is crucial care that should be proposed from the beginning of cancer treatment. More than the quantity of life, the quality of life is a primary goal when treating cancer in the older patients. An initial assessment of the frailty of the older patients should be carried out. The eight domains requiring in-depth assessment are social environment, functional status, walking and balance, cognition, psychological status, co-morbidity and polypharmacy, nutrition and sensory deficiencies. The alteration of these domains has an impact on the patient's outcome, his quality of life and the tolerance of the treatment. One of the major challenges is to maintain the autonomy of the older patient, which involves preserving his functional status, his neuropsychological state and his nutritional stat e. Corrective actions for each of the domains must be implemented and must be adjusted throughout the course. It is also important to anticipate risks that may compromise or delay the continuation of anti-tumor treatment such as falls, delirium, organ decompensation, iatrogenic risk and social isolation. PMID:35027163 | DOI:10.1016/j.bulcan.2021.12.004 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Update on recurrent mutations in angioimmunoblastic T-cell lymphoma

xlomafota13 shared this article with you from Inoreader Update on recurrent mutations in angioimmunoblastic T-cell lymphoma Via International Journal of Clinical and Experimental Pathology Int J Clin Exp Pathol. 2021 Dec 15;14(12):1108-1118. eCollection 2021. ABSTRACT Angioimmunoblastic T-cell lymphoma (AITL) is a subtype of peripheral T cell lymphoma (PTCL), defined by genetic alterations that induce abnormal immune activity and inflammatory disorders. Through recent discoveries using genomic studies, the identification of various recurrent mutations has provided greater insight and changed our understanding of the molecular genetics of the disease. By acknowledging these recurrent mutations and their affected pathways, the diagnosis, prognosis, treatment, and survival of AITL can be improved. In this review, we summarize the known recurrent mutations present in the molecular pathogenesis of AITL by emphasizing the effects of mutations on signaling pathways and genes, as well as the multistep process of AITL development. PMID:35027991 | PMC:PMC8748014 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Monitoring Spinal Cord Tissue Oxygen in Patients With Acute, Severe Traumatic Spinal Cord Injuries

xlomafota13 shared this article with you from Inoreader Monitoring Spinal Cord Tissue Oxygen in Patients With Acute, Severe Traumatic Spinal Cord Injuries Via leak of cerebrospinal fluid Crit Care Med. 2022 Jan 6. doi: 10.1097/CCM.0000000000005433. Online ahead of print. ABSTRACT OBJECTIVES: To determine the feasibility of monitoring tissue oxygen tension from the injury site (psctO2) in patients with acute, severe traumatic spinal cord injuries. DESIGN: We inserted at the injury site a pressure probe, a microdialysis catheter, and an oxygen electrode to monitor for up to a week intraspinal pressure (ISP), spinal cord perfusion pressure (SCPP), tissue glucose, lactate/pyruvate ratio (LPR), and psctO2. We analyzed 2,213 hours of such data. Follow-up was 6-28 months postinjury. SETTING: Single-center neurosurgical and neurocritical care units. SUBJECTS: Twenty-six patients with traumatic spinal cord injuries, American spinal injury association Impairment Scale A-C. Probes were inserted within 72 hours of injury. INTERVENTIONS: Insertion of subarachnoid oxygen electrode (Licox; Integra LifeSciences, Sophi a-Antipolis, France), pressure probe, and microdialysis catheter. MEASUREMENTS AND MAIN RESULTS: psctO2 was significantly influenced by ISP (psctO2 26.7 +/- 0.3 mm Hg at ISP > 10 mmHg vs psctO2 22.7 +/- 0.8 mm Hg at ISP <= 10 mm Hg), SCPP (psctO2 26.8 +/- 0.3 mm Hg at SCPP < 90 mm Hg vs psctO2 32.1 +/- 0.7 mm Hg at SCPP >= 90 mm Hg), tissue glucose (psctO2 26.8 +/- 0.4 mm Hg at glucose < 6 mM vs 32.9 +/- 0.5 mm Hg at glucose >= 6 mM), tissue LPR (psctO2 25.3 +/- 0.4 mm Hg at LPR > 30 vs psctO2 31.3 +/- 0.3 mm Hg at LPR <= 30), and fever (psctO2 28.8 +/- 0.5 mm Hg at cord temperature 37-38[degrees]C vs psctO2 28.7 +/- 0.8 mm Hg at cord temperature >= 39[degrees]C). Tissue hypoxia also occurred independent of these factors. Increasing the FIO2 by 0.48 increases psctO2 by 71.8% above baseline within 8.4 minutes. In patients with motor-incomplete injuries, fluctuations in psctO2 correlated with fluctuations in limb motor score. The injured cord spent 11% (39%) hours at psctO2 less than 5 mm Hg (< 20 mm Hg) in patients with motor-complete outcomes, compared with 1% (30%) hours at psctO2 less than 5 mm Hg (< 20 mm Hg) in patients with motor-incomplete outcomes. Complications were cerebrospinal fluid leak (5/26) and wound infection (1/26). CONCLUSIONS: This study lays the foundation for measuring and altering spinal cord oxygen at the injury site. Future studies are required to investigate whether this is an effective new therapy. PMID:35029868 | DOI:10.1097/CCM.0000000000005433 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Negative loop electrosurgical excision procedure (LEEP) following cervical biopsy diagnosis of high grade squamous intraepithelial lesion

xlomafota13 shared this article with you from Inoreader Negative loop electrosurgical excision procedure (LEEP) following cervical biopsy diagnosis of high grade squamous intraepithelial lesion Via International Journal of Clinical and Experimental Pathology Int J Clin Exp Pathol. 2021 Dec 15;14(12):1148-1154. eCollection 2021. ABSTRACT CONTEXT: Loop Electrosurgical Excision Procedure (LEEP) is commonly performed after cervical biopsy diagnosis of high grade squamous intraepithelial lesion (HSIL/CIN2 or CIN 3). Histological and immunohistochemical assessments are made to differentiate reactive and metaplastic changes from dysplastic changes. A Human Papillomavirus (HPV) test is used for prognostic assessment after conization. OBJECTIVE: We retrospectively reviewed cases where the cervical biopsy showed HSIL but the LEEP specimen was negative for high grade dysplasia. Our aim was to determine the cause of miscorrelation. DATA: IRB approval was obtained and a search was made of all LEEP specimens received during 2018. We reviewed 25 of 137 LEEP specimens that did not correlate with the diagnosis of HSIL rendered on the cervical biopsy. These were from women between 25 to 54 years . All cases had positive high-risk HPV with 80% being non16/18 subtype. On review, 8/25 had HSIL with the remainder of cases falling short of HSIL diagnosis. Follow up cytology with HPV test after the LEEP procedure was negative in all but one case of LSIL with persistent non-16/18 HPV. CONCLUSION: The study highlights the diagnostic difficulties of distinguishing HSIL from immature squamous metaplasia. The practical implication is that in cases with non-16/18 high risk HPV which have thin epithelium and fall short of definite morphologic criteria of HSIL, presence of immature squamous metaplasia should be carefully evaluated. The specific role of CK7 and CK17 which highlight squamocolumnar junctional cells and metaplastic cells, respectively, needs to be explored in these cases. PMID:35027995 | PMC:PMC8748010 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

A systematic review: metabolomics‐based identification of altered metabolites and pathways in the skin caused by internal and external factors

xlomafota13 shared this article with you from Inoreader A systematic review: metabolomics‐based identification of altered metabolites and pathways in the skin caused by internal and external factors Via Experimental Dermatology Abstract The skin's ability to function optimally is affected by many diverse factors. Metabolomics has a great potential to improve our understanding of the underlying metabolic changes and the affected pathways. Therefore, the objective of this study was to review the current state of the literature and to perform further metabolic pathway analysis on the obtained data. The aim was to gain an overview of the metabolic changes under altered conditions and to identify common and different patterns as a function of the investigated factors. A cross-study comparison of the extracted studies from different databases identified 364 metabolites, whose concentrations were considerably altered by the following factor groups: irradiation, xenobiotics, aging, and skin diseases (mainly psoriasis). Using metabolic databases and pathway analysis tools the individual metabolites were assigned to the corresponding metabolic pathways and the most strongly affected signaling pathways were identified. All factors induced oxidative stress. Thus, antioxidant defense systems, especially coenzyme Q10 (aging) and the glutathione system (irradiation, aging, xenobiotics) were impacted. Lipid metabolism was also impacted by all factors studied. The carnitine shuttle as part of β-oxidation was activated by all factor groups except aging. Glycolysis, Krebs (TCA) cycle and purine metabolism were mainly affected by irradiation and xenobiotics. The pentose phosphate pathway was activated and Krebs cycle was downregulated in response to oxidative stress. In summary, it can be ascertained that mainly energy metabolism, lipid metabolism, antioxidative defense and DNA repair systems were impacted by the factors studied. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Recommendations to protect patients with cancer against the Omicron variant

xlomafota13 shared this article with you from Inoreader Message: Préconisations pour protéger les patients de la filière oncologique face au variant OmicronRecommendations to protect patients with cancer against the Omicron variant Author links open overlay panelJérômeBarrière1GérardZalcman2LaurentFignon3NathanPeiffer-Smadja4ClarisseAudigier-Valette5MichelCarles6 https://doi.org/10.1016/j.bulcan.2021.12.007Get rights and content La protection contre le SARS-CoV-2 des patients suivis pour cancer sous traitement antinéoplasique est un enjeu prioritaire de la communauté oncologique depuis le début de la pandémie. Cet objectif s'est concrétisé en France par des actions fortes et rapides : la sanctuarisation « COVID-free » dès mars 2020 des services de chimiothérapie, l'accès prioritaire dès janvier 2021 [[1], [2]] à la vaccination et l'autorisation dès avril 2021 d'une troisième dose vaccinale précoce (DGS urgent avril 21) en cas de facteurs de risque d'immunodépression. Nous avons récemment proposé un arbre décisionnel en fonction du taux d'anticorps (Ac) anti-Spike (S) après la deuxième dose, dans le but d'identifier les patients pouvant bénéficier d'une troisième dose précoce, en priorisant ceux ayant un taux < 260 BAU/mL [3]. Il s'agissait là de permettre un schéma vaccinal complet accéléré pour répondre au variant Delta [4]. L'émergence en Europe [5] et dans le monde, fin 2021, du variant Omicron à forte contagiosité impose une réponse rapide. Ce variant est caractérisé par un échappement immunitaire partiel à important, à la fois contre l'immunité post-infectieuse, post-vaccinale et contre les anticorps monoclonaux anti-SARS-CoV-2, qui est lié à de nombreuses mutations de la protéine S [[6], [7]]. Plusieurs raisons justifient cette urgence. D'une part, l'émergence d'Omicron s'est partout traduite à ce jour par la disparition rapide des autres variants en circulation. C'est donc la souche qui menace aujourd'hui les patients y compris oncologiques. D'autre part, l'efficacité de la réponse immunitaire liée soit à une infection préalable par d'autres souches, soit à la vaccination, semble fragilisée par Omicron [[7], [8]]. Enfin, la neutralisation du SARS-Cov2 obtenue par les combinaisons d'anticorps monoclonaux anti-SARS-CoV-2 disponibles (casirivimab/imdevimab et tixagevimab/cilgavimab) apparaît sur les données préliminaires de tests de neutralisation in vitro nulle pour les premiers et très incertaine pour les derniers [9]. Or, ces anticorps, lorsqu'ils étaient administrés en prophylaxie permettaient de diminuer significativement le risque d'infection à SARS-CoV-2 (étude PROVENT, [10]) et, lorsqu'ils étaient administrés en traitement précoce, le risque de COVID-19 sévère [11]. Nous alertons la communauté oncologique sur le risque supplémentaire de COVID-19 grave lié à l'émergence du variant Omicron, pour les patients suivis pour cancer. Prenant en compte les données disponibles en population générale, ce risque est majeur dans la population oncologique, comme pour d'autres populations immunodéprimées (thérapies ciblées anti-CD20 par exemple). Néanmoins, la quantification précise de ce risque en termes d'hospitalisation et de décès n'est pas connue à ce jour. Afin d'anticiper cette nouvelle menace, à la fois du point de vue du risque de contagiosité que de l'échappement à la réponse immune, nos six propositions sont les suivantes : Proposition 1 : recommander une troisième dose vaccinale pour tous avec contrôle du taux résiduel d'Ac anti-S à trois mois. Face au variant Omicron, les données déjà disponibles objectivent une diminution de l'efficacité vaccinale plus rapide que par rapport au variant Delta, avec manifestement une protection accrue du booster (dose 3) [12]. Le niveau d'Ac anti-S obtenu après une dose 3 a été rapporté environ neuf fois supérieur qu'après une dose 2 dans la population générale [13]. En oncologie les données sont encore trop peu nombreuses mais certains patients semblent tirer nettement bénéfice du boosteravec des taux d'Ac anti-S sous chimiothérapie qui dépassent les taux atteints après deux doses [14], qui rappelons-le demeurent significativement inférieurs à la population générale à quatre semaines de la dose 2 [15]. Recommander la dose 3 précocement (à trois ou quatre mois de la dose 2) pour tous les patients oncologiques désormais (certains n'ont à ce jour encore uniquement reçu deux doses), et administrer une dose 4 pour ceux ayant déjà fait leur dose 3 depuis trois à quatre mois en fonction du taux d'Ac anti-S résiduel, apparaît opportun pour tenter de protéger au mieux ces patients face au variant Omicron qui nécessite un taux d'anticorps protecteurs plus élevés que face aux précédents variants. Ayant montré que les traitements par anticorps anti-CD20 constituent un facteur de risque majeur d'absence de réponse humorale à la vaccination chez les patients atteints de leucémie lymphoïde chronique ou lymphome, même avec une troisième dose vaccinale précoce [16], la dose 4 a cependant très peu de chances d'être efficace dans ce sous-groupe de patients. Proposition 2 : retenir le seuil de 1000 BAU/mL comme taux d'Ac anti-S pour une dose vaccinale additionnelle (dose 4). Si le taux d'anti-S mesuré est < 1000 BAU/mL, une dose additionnelle est proposée. Ce seuil correspond en effet à celui obtenu environ trois à quatre mois après dose 2 dans une population sans comorbidité [17] et à qui désormais une dose 3 est proposée de manière anticipée pour conférer rapidement une protection sérologique optimale face à Omicron. Ce seuil pourrait donc être la valeur retenue pour la surveillance des patients immunodéprimés, en particulier les patients oncologiques, afin de proposer une dose vaccinale additionnelle, c'est-à-dire une dose 4. Proposition 3 : prescription en prophylaxie primaire pré-exposition de l'association d'anticorps monoclonaux tixagevimab/cilgavimab (EVUSHELD®, AstraZeneca), pour les patients sans séroconversion après dose 3–4. Cette association d'anticorps à demi-vie longue demeure efficace in vitro sur le variant Delta. Lorsque Omicron sera le variant majoritaire, le risque de perte de sensibilité décrit in vitro devrait alors faire prioriser l'anticorps sotrovimab (XEVUDY®, GSK) [18] semblant moins affecté in vitro par les mutations d'Omicron [9] même si les données d'efficacité clinique de l'association tixagevimab/cilgavimab face à Omicron pourraient s'avérer suffisantes, avec possiblement la nécessité d'une deuxième administration précoce pour maintenir un taux élévé des anticorps dans le sang ou d'une augmentation de la dose. Actuellement seuls les patients atteints d'hémopathies lymphoïdes ou ayant reçu une greffe de cellules souches hématopoïétiques sont éligibles en oncologie à la procédure d'accès précoce. Il nous semble opportun d'élargir à l'ensemble de la population oncologique sous traitement actif les indications, face au risque omicron, en l'absence de séroconversion après un schéma vaccinal à quatre doses. Le seuil de 264 BAU/mL actuellement seuil de prescription reste à préciser face au variant Omicron et pourrait nécessiter un relèvement à 1000 BAU/mL. Proposition 4 : vaccination complète (trois doses) pour les proches des patients sous chimiothérapie. Nous recommandons également la vaccination des enfants de cinq à onze ans en contact de parents immunodéprimés, en accord avec la plupart des sociétés savantes pédiatriques mondiales et les autorités américaines (FDA) et européennes (EMA) du médicament. Proposition 5 : port d'un masque de protection de type Filtering Face Piece type 2 (FFP2/N95) pour les patients en cours de traitement actif, dont certains (avec cancer pulmonaire, hémopathie lymphoïde…) ont un risque de décès de 30 % ou plus en cas de contamination, dans les lieux avec du public. De récentes données comparatives en conditions expérimentales évaluent une protection individuelle supérieure par rapport au port de masques chirurgicaux [19]. Le gain peut apparaître cependant limité si le port des masques chirurgicaux était bien respecté par tous, mais cette condition apparaît peu réaliste dans les lieux avec public (cinéma, transports en commun etc.) ou encore lors des transports en VSL/ambulance, voire lors des séances de chimiothérapie en salle commune. La protection d'un masque de type FFP2 nous apparaît ainsi être une recommandation basée sur le principe de précaution (accord d'experts) en période de forte circulation virale d'un agen t pathogène très contagieux pour protéger une population immunodéprimée. Ces masques représentent un surcoût non négligeable par rapport aux masques dits chirurgicaux simples, eux remboursés. Nous recommandons donc de manière rapide leurs remboursements sur prescription médicale. Proposition 6 : favoriser si disponibilité l'inclusion des patients suivis pour une néoplasie dans les essais thérapeutiques innovants que ce soit en prophylaxie primaire ou post-exposition, en cas de PCR positive en ciblant les anticorps monoclonaux ou thérapies antivirales à venir telles que l'association PF-07321332 et ritonavir (PAXLOVID®, Pfizer) dont les données d'efficacité contre le variant Omicron, ou dans une population immunodéprimée ne sont pas encore connues. En conclusion, la mise en œuvre de ces six propositions est de nature à protéger au mieux les patients suivis pour cancer, en particulier ceux en soins actifs, avec des données suffisantes pour formuler des recommandations complètes associant plusieurs mesures de protection qui prennent en compte le risque d'inefficacité vaccinale. Dans un contexte de reprise épidémique avec un nouveau variant hautement contagieux et échappant au moins partiellement à l'immunité acquise, nous n'avons pas le temps d'attendre des études à plus large échelle. Pour les patients immunodéprimés, c'est une menace immédiate dès janvier 2022 à laquelle nous devons apporter une réponse rapide, qui s'adaptera aux futures informations dès qu'elles seront disponibles. Financement aucun. Déclaration de liens d'intérêts M. Carles, N. Peiffer-Smadja et L. Fignon déclarent ne pas avoir de liens d'intérêts. Références [1] J.P. Spano, F. Barre-Sinoussi, M.P. Kieny, A.G. Marcelin, J.Y. Blay Vaccination anti COVID-19 pour les personnes souffrant de cancer : un impératif médical et éthique [COVID-19 vaccination for cancer patients: Medical and ethical need] Bull Cancer, 108 (3) (2021), pp. 225-227, 10.1016/j.bulcan.2021.02.001 [French. Epub 2021 Feb 16] ArticleDownload PDFView Record in ScopusGoogle Scholar [2] J. Barrière, C. Audigier-Valette, D. Borchiellini, B. Hoch, O. Castelnau, E. François, et al. Nous devons respecter le schéma vaccinal anti-SARS-CoV-2 sans décalage chez les patients atteints de cancer sous traitement [We must respect the anti-SARS-CoV-2 vaccine schedule without delay in cancer patients under treatment] Bull Cancer, 108 (4) (2021), pp. 341-342, 10.1016/j.bulcan.2021.02.003 French. Epub 2021 Mar 5 ArticleDownload PDFView Record in ScopusGoogle Scholar [3] J. Barrière, M. Carles, C. Audigier-Valette, D. Re, A. Zoubir, B. Seitz-Polski, et al. Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position paper Eur J Cancer (2021), 10.1016/j.ejca.2021.12.011 [S0959804921012752] Google Scholar [4] J. Barrière, D. Re, F. Peyrade, M. Carles Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer Eur J Cancer, 154 (2021), pp. 66-72, 10.1016/j.ejca.2021.06.008 ArticleDownload PDFView Record in ScopusGoogle Scholar [5] Weekly epidemiological update: Omicron variant of concern (VOC)–week 50 (data as of 19 December 2021). https://www.ecdc.europa.eu/en/news-events/weekly-epidemiological-update-omicron-variant-concern-voc-week-50-data-19-december-2021. Google Scholar [6] V.M. Ferré, N. Peiffer-Smadja, B. Visseaux, D. Descamps, J. Ghosn, C. Charpentier Omicron SARS-CoV-2 variant: what we know and what we don't Anaesth Crit Care Pain Med, 41 (1) (2021), p. 100998, 10.1016/j.accpm.2021.100998 Google Scholar [7] J.R.C. Pulliam, C. van Schalkwyk, N. Govender, A. von Gottberg, C. Cohen, M.J. Groome, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa medRxiv (2021) [2021.11.11.21266068] Google Scholar [8] L. Lu, et al. Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients Clin Infect Dis (2021), 10.1093/cid/ciab1041 [ciab1041] Google Scholar [9] D. Planas, et al. Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization (2021), 10.1101/2021.12.14.472630 http://biorxiv.org/lookup/doi/10.1101/2021.12.14.472630 Google Scholar [10] "AZD7442 request for Emergency Use Authorization for COVID-19 prophylaxis filed in US". AstraZeneca (Press release). 2021. Retrieved 15 October 2021. Google Scholar [11] D.M. Weinreich, S. Sivapalasingam, T. Norton, S. Ali, H. Gao, et al. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19 N Engl J Med, 385 (23) (2021), p. e81, 10.1056/NEJMoa2108163 CrossRefView Record in ScopusGoogle Scholar [12] H. Gruell, et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant (2021), 10.1101/2021.12.14.21267769 http://medrxiv.org/lookup/doi/10.1101/2021.12.14.21267769 Google Scholar [13] D.H. Canaday, O.A. Oyebanji, E. White, D. Keresztesy, M. Payne, D. Wilk, et al. Significantly elevated antibody levels and neutralization titers in nursing home residents after SARS-CoV-2 BNT162b2 mRNA booster vaccination medRxiv [Preprint] (2021), 10.1101/2021.12.07.21267179 [2021.12.07.21267179] Google Scholar [14] V. Gounant, et al. Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses J Thorac Oncol (2021), 10.1016/j.jtho.2021.10.015 [S155608642103286X] Google Scholar [15] J. Barrière, et al. Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors Ann Oncol, 32 (2021), pp. 1053-1055 ArticleDownload PDFView Record in ScopusGoogle Scholar [16] D. Re, et al. Humoral and cellular responses after a third dose of BNT162b2 vaccine in patients treated for lymphoid malignancies (2021), 10.1101/2021.07.18.21260669 http://medrxiv.org/lookup/doi/10.1101/2021.07.18.21260669 Google Scholar [17] A. Israel, Y. Shenhar, I. Green, E. Merzon, A. Golan-Cohen, A.A. Schäffer, et al. Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection medRxiv [Preprint] (2021), 10.1101/2021.08.19.21262111 [2021.08.19.21262111] Google Scholar [18] A. Gupta, Y. Gonzalez-Rojas, E. Juarez, M. Crespo Casal, J. Moya, D.R. Falci, et al. Early treatment for covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab N Engl J Med, 385 (21) (2021), pp. 1941-1950, 10.1056/NEJMoa2107934 CrossRefView Record in ScopusGoogle Scholar [19] G. Bagheri, B. Thiede, B. Hejazi, O. Schlenczek, E. Bodenschatz An upper bound on one-to-one exposure to infectious human respiratory particles Proc Natl Acad Sci U S A, 118 (49) (2021), 10.1073/pnas.2110117118 [e2110117118] Google Scholar View Abstract © 2021 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved. Recommended articles Linkage and association of PAX7 polymorphisms (rs742071, rs766325, and rs4920520) with the risk of non-syndromic cleft lip with/without cleft palate: A systematic review and meta-analysis Meta Gene, Volume 31, 2022, Article 101007 Purchase PDFView details Quand évoquer une maladie héréditaire du métabolisme devant des troubles de conscience? Journal Européen des Urgences et de Réanimation, Volume 28, Issue 1, 2016, pp. 39-41 Purchase PDFView details Two methodologies of the rendezvous procedure to establish ureteral continuity from a delayed ureteral leak following pelvic surgery Surgical Oncology, Volume 40, 2022, Article 101697 Purchase PDFView details 12Next Citing articles (0) Elsevier logo About ScienceDirect Remote access Shopping cart Advertise Contact and support Terms and conditions Privacy policy We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2022 Elsevier B.V. or its licensors or contributors. ScienceDirect ® is a registered trademark of Elsevier B.V. RELX group home page Provide feedback Recommendations to protect patients with cancer against the Omicron variant Via Association française pour l'étude du cancer Bull Cancer. 2022 Jan 11:S0007-4551(21)00685-8. doi: 10.1016/j.bulcan.2021.12.007. Online ahead of print. NO ABSTRACT PMID:35031126 | DOI:10.1016/j.bulcan.2021.12.007 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Magnesium alginate versus proton pump inhibitors for the treatment of laryngopharyngeal reflux: a non-inferiority randomized controlled trial

xlomafota13 shared this article with you from Inoreader Magnesium alginate versus proton pump inhibitors for the treatment of laryngopharyngeal reflux: a non-inferiority randomized controlled trial Via http://link.springer.com/journal/405,European archives of oto-rhino-laryngology,The European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino Eur Arch Otorhinolaryngol. 2022 Jan 15. doi: 10.1007/s00405-021-07219-0. Online ahead of print. ABSTRACT PURPOSE: Proton pump inhibitors (PPIs) are commonly prescribed for laryngopharyngeal reflux (LPR), but their efficacy remains debated. Alginates is an option for the treatment of LPR with few adverse effects. The study aimed to investigate the non-inferiority of an alginate suspension (Gastrotuss®) compared to PPIs (Omeprazole) in reducing LPR symptoms and signs. METHODS: A non-inferiority randomized controlled trial was conducted. Fifty patients with laryngopharyngeal symptoms (Reflux Symptom Index -RSI- ≥ 13) and signs (Reflux Finding Score -RFS- ≥ 7) were randomized in two treatment groups: (A) Gastrotuss® (20 ml, three daily doses) and, (B) Omeprazole (20 mg, once daily). The RSI and the RFS were assessed at baseline and after 2 months of treatment. RESULTS: Groups had similar RSI and RFS scores at baseline. From pre- to 2-month posttreatment, the mean RSI significantly decreased (p = 0.001) in alginate and PPI group (p = 0.003). The difference between groups in the RSI change was not significant (95%CI: - 4.2-6.7, p = 0.639). The mean RFS significantly decreased in alginate (p = 0.006) and PPI groups (p = 0.006). The difference between groups in the mean change RFS was not significant (95%CI: - 0.8; 1.4, p = 0.608). CONCLUSION: After 2 months of treatment, LPR symptoms and signs are significantly reduced irrespective of the treatment. Alginate was non-inferior to PPIs and may represent an alternative treatment to PPIs for the treatment of LPR. PMID:35032204 | DOI:10.1007/s00405-021-07219-0 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.